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Abstract
Graves’ disease is an autoimmune disease. It accounts for 50–80% of cases of hyperthyroidism. Antibodies against the TSH 
receptor (TRAb) are responsible for hyperthyroidism (TRAB). The key role in monitoring and diagnosis of Graves’ disease plays 
the level of hormones of free thyroxine and triiodothyronine. Helpful is an ultrasound of the thyroid scintigraphy which due to 
its functional character is both a valuable addition to morphological studies as well as plays an important role in the diagnosis 
and therapy in patients with Graves’ disease. There is no perfect treatment for Graves’ disease. The reason for this is the lack 
of therapy directed against primary pathogenic mechanisms. Currently available treatments need to be thoroughly discussed 
during the first visit as the patient’s understanding of the choice of a treatment constitutes a vital role in the success of therapy. 
Graves’ disease treatment is based on three types of therapies that have been carried out for decades including: pharmacologi-
cal treatment anti-thyroid drugs, I131 therapy and radical treatment — thyroidectomy. The purpose of the treatment is to control 
symptoms and patient to return to euthyreosis. Treatment of Graves’ disease is of great importance because if left untreated, 
it can lead to long-term harmful effects on the heart, bone and mental well-being of patients.
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(TRAb) are responsible for hyperthyroidism (TRAB) [8, 9]. These 
antibodies, on the surface of thyroid cells, link with TSH receptors, 
causing uncontrolled and continuous stimulation of the thyroid, 
leading to excessive synthesis of the thyroid hormones: thyroxine 
(T4) and triiodothyronine (T3) and its hypertrophy. The spontane-
ous remission of the disease occurs in 30% of patients [8].
Nuclear medicine allows performing both diagnosis and treat-
ment of Graves’ disease. The aim of this review is to show the 
current approach to diagnosis and therapy of Graves’ disease, 
particularly putting the particular emphasis on paying attention 
to the methods used in nuclear medicine, which may be useful 
to GP doctors and specialists providing care for patients with 
Graves’ disease.
Diagnosis of Graves’ disease
A full-blown picture of hyperthyroidism is often seen in pa-
tients aged 20–50 years. In the elderly, symptoms may be hardly 
visible, often in the form of thyroid-heart set [10]. Clinical signs and 
symptoms of the disease are divided into different forms of hy-
perthyroidism [9, 11]. Graves’ disease is associated with beyond 
thyroid symptoms including symptoms around the eye sock-
Background
Graves’ disease is one of the most common autoimmune 
diseases. It affects around 5% of the population and accounts for 
50–80% of cases of hyperthyroidism [1, 2]. The number of cases 
is about 24 per 100,000 patients per year [3]. The incidence of the 
disease is similar among White Race and Asians Race, but it is lower 
among blacks. The greatest risk of developing the disease falls on 
women aged 40–60 years [4]. In the United States Graves’ disease 
is the most common cause of hyperthyroidism and its occurrence 
is approx. 1.2% [5]. Genetic and environmental factors (80%: 20%) 
are responsible for the rise of the disease. Environmental factors in-
clude: smoking, stress, pregnancy, sex hormones, infections and 
adequate consumption of iodine [6–8]. The immunopathogenesis of 
Graves’ disease is complex. Antibodies against the TSH receptor 
111www.nmr.viamedica.pl
Karolina Prasek et al., Diagnosis and treatment of Graves’ disease
Review
ets (Graves’ ophthalmopathy) and less common symptoms: skin 
lesions (thyroid dermopathy), and the swelling around fingers and 
nails (thyroid acropachia) [10, 12–15]. Orbitopathy is characterized 
by inflammation of oculomotor muscles and extraocular connective 
tissue. It occurs in about one-third of patients. It is unique for Graves’ 
disease. Thyrotropin receptors located on orbit fibroblasts and 
adipocytes are probably responsible for autoimmune features of 
Graves’ ophthalmic [17]. In addition, in Graves’ disease vascular 
goiter can be detected, making it easy to recognize, because the 
disease occurs rarely without the goiter [10]. When these charac-
teristic symptoms occur in combination with diffuse goiter and 
hyperthyroidism, the diagnosis of this disease is easy. However, 
in the case of patients without symptoms of hyperthyroidism or 
ocular symptoms and lack of goiter, Graves’ disease should be 
differentiated from other causes of hyperthyroidism such as toxic 
adenoma or toxic multinodular goiter. Larger diagnostic difficul-
ties occur in the elderly, in whom hyperthyroidism occurs in the form 
of thyroid-heart set and in patients with Graves’ ophthalmopathy 
without symptoms of hyperthyroidism (the so-called euthyreosis in 
Graves’ disease) [8, 9, 16, 18].
Laboratory studies
In 2011 there was a major international survey conducted 
among members of the Endocrine Society, the American Thyroid 
Association (ATA) and the American Association of Clinical endo-
crinologists (AACE) to oversee Graves’ disease. The majority of 
respondents came from North America (63%), while the others were 
from Europe (12.9%), South America (11.3%), Asia and Oceania 
(9.5%), Middle East and Africa (3.4 %) [8, 19]. A study showed that 
90% of endocrinologists in case of suspicion of hyperthyroidism re-
quire the measurement of TSH and FT4 free thyroxine concentration. 
This approach is consistent with the guidelines of the AACE and ATA 
in the diagnosis of hyperthyroidism, therefore the finding of reduced 
levels of TSH and the increase level of FT4 is usually sufficient to 
diagnose Graves’ disease despite the fact that the concentration 
of FT3 is also often elevated in patients with hyperthyreosis [5, 8]. 
A study on the level of FT3 was only needed for 40% of endocrinolo-
gists involved in the survey (without geographical differences) [19]. 
However, 2-4% of patients with hyperthyroidism have the correct 
level of FT4 and increased level of FT3, T3 (i.e. T3 thyrotoxicosis) 
[8, 11]. Thus, in the initial assessment of status of thyroid in case 
of patients with suspected hyperthyroidism it is recommended that 
the measurement of concentration level of TSH, FT4 and FT3 in the 
serum should take place.
To determine whether the cause of hyperthyroidism is Graves’ 
disease, a designation in the serum of the concentration level of 
antibodies against the TSH receptor (TRAB) is advisable. Due to 
the fact that antibodies against thyroglobulin (anti-Tg) and thyroid 
peroxidase (anti-TPO) are found both in patients with the disease 
of Hashimoto as well as in patients with Graves’ disease, modern 
immunological and biological tests for TRAb with high sensitivity 
and specificity allow to identify the etiology of hyperthyroidism [8, 
20–23]. A designation of antibodies against THS receptor (TRAB) 
takes place in a short time, because the current automated 
TRAb tests developed over the last 5–10 years are comparable 
to tests helping determine the level of antibodies against thyroid 
peroxidase (TPO) in terms of ease of use and costs of implementa-
tion. A meta-analysis published in 2012 showed that the sensitivity 
of TRAb tests of the third generation is respectively 98.3% and 
specificity is 98.2%. The probability that the patient has Graves’ 
disease is 1.367–3.420 times higher in the case, when antibody 
against TSH receptor are positive than negative [8, 24, 25].
In a study from 2011 concentration measurement of TRAb 
antibodies was practiced by 58.1% of respondents: including in 
Europe (77.5%), South America (54.3%) and also by 65.3% of 
respondents from Asia and Oceania [8, 26]. The measurement of 
TRAb in patients with hyperthyroidism is a helpful test in establish-
ing the diagnosis, which often helps predict the clinical course 
and response to treatment. This study plays a special role in 
ambiguous clinical cases, such as: painless thyroiditis, unilateral 
exophthalmos, Graves’ opthalmopathy in the condition of euthy-
reosis, subclinical hyperthyroidism, hyperthyroidism induced by 
amiodarone, hyperemesis gravidarum, with a hyperthyroidism 
and anticipating the risk of neonatal hyperthyroidism in moth-
ers with Graves’ disease [27]. Due to the much higher sensitivity, 
and low cost to measure the concentrations of antibodies against 
the TSH receptor, this test should be performed in every patient 
suspected of having Graves’ disease, especially in the absence of 
symptoms beyond thyroid including Graves’ ophthalmopathy [8].
Image exploration and the iodine uptake test
Ultrasound examination on thyroid, belonging to the screening 
examinations, helps in its diagnosis. It is inexpensive, non-invasive, 
repeatable, which allows diagnosing breast-feeding mothers, 
pregnant women giving immediate results and documentation in 
the form of photos of tested thyroid. The ultrasound examination al-
lows assessing echostructure of pulp, highlighting focal lesions, as-
sessing their vasculature by using Color Doppler Ultrasonography, 
as well as diversifying them into solid and cystic changes [8, 28]. 
Under the control of ultrasonography a fine needle biopsy can be 
performed, which determines a type of change we face: mild or 
cancer change. It is useful in the diagnosis of lumpy version of 
Graves’ disease and autoimmune toxic nodular goiter [8]. In pa-
tients with Graves’ disease usually an increased hipoechogenicity 
of pulp is stated during the ultrasound examination.
Among 426 patients with Graves’ disease, USG examination 
made it possible to determine the correct ultrasound diagnosis in 
406 patients (95.2%), while scintigraphy led to the correct diagno-
sis in 415 patients (97.4%) [8, 29].
Image tests used in nuclear medicine include: scintigraphy 
and the iodine uptake test. Scintigraphy is based on a physiologi-
cal phenomenon that consists of the ability to actively uptake of 
iodine. It is due to the presence of proteins in the basal membrane 
— sodium-iodine thyrocyte symporter [30]. The scintigraphy is per-
formed with a metastable technetium (Tc99m) or by using radioac-
tive iodine. The iodinated isotopes, in the examination, emit gamma 
radiation that is registered by means of a gamma camera. The 
intensity of tracer accumulation is proportional to the thyroid. The 
isotope of iodine which is used in scintigraphic examination is I131. 
Scintigraphy is based on the assumption that the affected pulp of 
thyroid has a different ability to uptake technetium radioisotopes and 
iodine than normal pulp [30, 31]. Improper placement of a given 
compound indicates the presence of pathological changes in the 
thyroid gland [31]. The routine scintigraphy is administered intra-
venously at a dose of 40–60 MBq (1–2 mCi). Radioactive iodine 
is administered orally at a dose of 2–4 MBq (74–148 μCi) [30, 31]. 
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In Graves’ disease equally increased radiotracer uptake by the thy-
roid gland is reported. Due to the increased turnover of iodine and 
increased hormone synthesis, you can observe greater radiotracer 
uptake after 4–6 hours, and after 24 hours [8, 30]. According to the 
current guidelines of AACE and ATA, the uptake of radioactive iodine 
by the thyroid should be measured in patients with symptoms of 
hyperthyroidism; however it does not prove Graves’ disease [8].
Treatment of Graves’ disease
The ideal therapy for Graves’ disease should restore the proper 
function of the thyroid gland, prevent the recurrence of hyperthyroid-
ism, avoid development of hypothyroidism and not allow progres-
sion of Graves’ ophthalmopathy. Unfortunately, current therapies do 
not meet the above criteria. Each patient, therefore, should be 
aware of their advantages and disadvantages. Treatment of Graves’ 
disease is based on three types of therapies that are carried out for 
decades including: pharmacological treatment anti-thyroid drugs, 
I131 therapy and radical treatment — thyroidectomy. The purpose 
of the treatment is to control symptoms and patient to return to 
euthyreosis [32]. In the United States the most common treatment 
for Graves’ disease chosen by doctors is I131 therapy, while in Europe 
and Japan, there is a greater preference for medical and radical 
treatment [5]. Treatment of Graves’ disease is of great importance 
because if left untreated it can lead to long-term harmful effects on 
the heart, bone and mental well-being of patients [32, 33].
Pharmacotherapy
The most commonly used group of anti-thyroid drugs in pa-
tients with Graves’ disease are thionamides which were introduced 
in 1943 by Astwood [34]. This group includes: methimazole (MMI), 
propylthiouracil (PTU) and carbimazole (CBZ); they are the ba-
sis of anti-thyroid therapy. Their main effect is to inhibit the synthe-
sis of thyroid hormone by blocking the action of thyroid peroxidase 
as a consequence of incorporation of iodine to thyroglobulin, which 
is an important step in the synthesis of triiodothyronine (T3) and 
thyroxine (T4) [34, 35].
Anti-thyroid drugs which do not belong to thionamides group, 
nowadays rarely used, is also potassium perchlorate recommended 
in hyperthyroidism induced by amiodarone [8].
Among the thyrostatic drugs the following are the most 
frequently applied in practice: propylthiouracil (Thyrosan®) and 
thiamazole (Thyrozol®: 5, 10, 20 mg, Metizol® 5 mg). Anti-thyroid 
drug therapy is continued for a period of 9 to 12 months, but in 
appropriate cases from 18 to 24 months [36]. The current ATA 
and AACE guidelines indicate that methimazole should be taken 
for a period of approximately 12–18 months and then that dose 
should be reduced or discontinued if TSH at this time is normal. 
Note that the anti-thyroid drugs do not cure Graves’ hyperthyroid-
ism, however in the case of suitable doses this drug may be very 
effective what enables to control hyperthyroidism and allows for 
the euthyreosis [5]. Anti-thyroid drugs can inhibit the production 
of thyroid hormone, but they also have topical immunesuppres-
sive activity as a result of which a decrease in the concentration of 
anti-TSHR occurs [10].
Pharmacological treatment of Graves’ disease starts with a full 
dose of thyrostatic drug gradually decreasing it according to the 
results of the concentration of free hormones in the serum and the 
clinical condition of the patient. In case of the correct drug reaction 
after 2–3 weeks of treatment an improvement is noticed, whereas af-
ter 4–6 weeks euthyreosis appears. In cases of non-radioiodine 
therapy or surgery in 20% of patients have a permanent remission 
of the disease, while after about 6–9 months after treatment 50% 
of patients are still in euthyrosis [36]. Higher doses of anti-thyroid 
drugs allow obtaining euthyroid state faster, however, they do not 
increase the chance of securing a lasting remission and their use 
increases the risk of side effects [10].
The current AACE and ATA guidelines suggest that methima-
zole should be used in all cases of patients eligible for anti-thyroid 
treatment, except for women in the first trimester of pregnancy 
[5, 8]. Furthermore, doctors should prescribe pregnant women 
propylthiouracil (PTU) due to the risk of embryopathy associated 
with taking methimazole and carbimazole [5, 8].
A study published in 2010 by Emiliano et al. [37] shows that 
methimazole is the most commonly prescribed anti-thyroid drug 
since 1996 in the United States. There is a growing popularity of it 
as nowadays doctors prescribe it 9 times more frequently [8, 37].
Supportive therapy involves the administration of sedatives, 
and b-adrenolytics. If necessary in the initial stage of Graves’ 
disease and in case of leucopenia, prednisone can be prescribed 
for patient at a dose 10–20 mg per day [36]. Supportive therapy 
is mainly used in the initial phase of anti-thyroid treatment to reduce 
the symptoms of hyperthyroidism [8]. If the patient after comple-
tion of treatment with methimazole falls again in hyperthyroidism 
this qualifies him to radioiodine therapy or thyroidectomy.
Each patient during drug therapy should be informed of side 
effects of anti-thyroid drugs. Patient should inform your doctor 
immediately if he/she experiences jaundice, rashes, joint pain, 
abdominal pain, dark colored urine, fever, nausea, fatigue or sore 
throat. Before starting treatment, you should also inform the patient 
to immediately stop taking the medicines and report to their doctor if 
symptoms suggesting agranulocytosis or liver damage develop [5]. 
Also when cutaneous allergic symptoms are observed antihistamine 
may be included in order to relieve these. Cross-reaction between 
propylthiouracil and thiamazole occurs in approximately 50% of 
cases. Alternatively, a lithium or inorganic iodine can be used [36].
Anti-thyroid treatment is recommended especially in patients with 
a high likelihood of remission (especially women with mild disease 
with low crop and the negative or low titer of TRAb). Pharmacological 
treatment is also advised in the elderly with underlying conditions that 
increase the risk of surgery, patients living in nursing homes and 
other care facilities, as preparation for radioiodine administration, 
which reduces the need for daily administration of thyreostatics [5].
The main disadvantage of pharmacological treatment is a high 
rate of relapse of Graves’ disease. It varies from 30 to 70% in different 
studies [38, 39]. Factors that are associated with a high likelihood 
of relapse after treatment with anti-thyroid are: young age, sex, 
smoking, postnatal period as well as severe hyperthyroidism. The 
increased risks of relapse are also encountered in patients who at 
the end of the treatment have the increased level of TRAb antibodies, 
but recurrence can also happens to a lesser extent in patients with 
normal levels of antibodies against the TSH receptor [8].
New therapeutic options
Because of autoimmune etiopathogenesis of Graves’ disease 
immunomodulatory therapy has been recently attempted. High 
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hopes were placed in the use of rituximab (anti-CD20). Unfortu-
nately, the first results of clinical studies indicate its limited effective-
ness which at high cost and aggressiveness of therapy does not 
encourage its use [36].
Surgical treatment — thyroidectomy 
(thyroidectomy)
Thyroidectomy is an effective way to treat hyperthyroidism, 
however, is less common than radioiodine therapy [40–42]. It can 
be implemented only in patients treated with anti-thyroid [8, 43, 44]. 
Thyroidectomy should be considered in the following cases: pa-
tients with a large goiter, patients not responding to treatment with 
anti-thyroid drugs or patients, who refuse radioiodine therapy. Such 
a phenomenon is often observed in Asian countries [45]. Thyroid-
ectomy should be also performed in women in the second trimester 
of pregnancy, after failure of treatment with anti-thyroid drugs, in the 
period in which radioiodine therapy is contraindicated, as well as in 
cases where there is a fear of progress and ophthalmic resulting from 
the treatment of I131. The treatment should also be considered in any 
patient with nodular form of Graves’ disease, in which fine-needle 
biopsy of the nodule indicates the presence of malignant thyroid and 
in scintigraphy a “cold nodule” is stated [46]. The incidence of hypo-
thyroidism is associated with a range of treatment. It is considered 
that hypothyroidism occurs in approximately 50% of patients after 
age of 25 [40, 46]. In some centers in patients with low crop with-
out suspicion of cancer the macroscopic visual treatments using 
an endoscope are implemented, which cause less operative 
trauma compared to conventional open access [8, 47]. Specific 
complications after thyroidectomy are as the following: recurrent 
laryngeal nerve damage and post-surgical wound infection [8, 46]. 
These complications are inversely correlated with the experience 
of the surgeon and the annual number of such procedures [48]. 
The advantage of thyroidectomy is above all the fast relief of hy-
perthyrodism, while the disadvantages are as the following: general 
anesthesia, complication among 1–2% of patients such as recurrent 
laryngeal nerve palsy, hypoparathyroidism [46].
A preparation for surgery usually involves the administration of 
anti-thyroid drugs to restore euthyreosis and providing a solution 
of potassium iodide in 10–14 days to reduce congestion thyroid 
thereby reducing the intra-operative blood loss. Thyroidectomy 
seems to have no impact on the natural course of Graves’ ophthal-
mopathy, but in its aftermath, cannot be ruled out beneficial effect of 
treatment due to a decrease in the serum antibody levels of TRAb. 
The results of a randomized prospective study show that the decline 
in the level of TRAb antibodies in the serum does not prevent the 
development of eye diseases. In case of 16 out of 191 patients with 
Graves’ ophthalmopathy mild symptoms were observed over the 
next 5 years [8, 49].
Radioiodine therapy (I131)
A treatment of Graves’ disease with radioactive iodine was in-
troduced in 1940 in order to provide an alternative to surgical treat-
ment of hyperthyroidism. In Poland, therapy with I131 is routinely 
carried out in the treatment of hyperthyroidism, including Graves’ 
disease since 1950. Since that time, it has become widely used 
in the treatment of thyroid diseases making gradual necrosis of 
the thyroid cells [17, 50]. Loss of functional thyroid tissue after 
treatment with radioiodine in the majority of patients ultimately 
leads to its hypo-function, which is the desired effect of treatment 
with I131 [8, 17]. The use of low doses of this isotope is to restore 
the euthyroid state, but it is associated with a high rate of relapse 
of hyperthyroidism [5].
I131 is available in the form of sodium iodide (NaI) for oral ad-
ministration in the form of capsules or liquid. The most commonly 
used forms are capsules, because the use of fluid is associated 
with a higher risk of contamination. They are supplied by the manu-
facturer in a variety of activities depending on demand. Under the 
current rules, capsules are transported and stored in containers with 
a capacity to absorb beta and gamma radiation. I131 capsules are 
administered to the individual via the respective applicators for 
reducing or eliminating the risk of direct contact with the skin of 
the capsule and its drop.
The effectiveness of the treatment of Graves’ disease largely 
depends on the therapeutic activity of the I131. The selection of 
optimal activity is difficult, high therapeutic doses give the high-
est cure rates, but relatively often cause hypothyroidism. On the 
other hand, the low activity less likely lead to hypothyroidism, but 
their effectiveness is poor. In addition, as shown by many years of 
experience, the effectiveness of radioiodine therapy of Graves’ 
disease is influenced by a number of factors, many of which are im-
measurable and they cannot be all included in one chart. Currently, 
there are two methods of determining therapeutic activity: solid 
dosage and method based on individual calculation of the dose. 
Recommended current activities of I131 were selected empirically. 
Activity of I131 (A) is calculated by taking into account the desired 
absorbed dose (D), the target tissue mass (m) and a maximum 
of thyroid iodine uptake (U), according to the following formula:
A [MBq] = 27.2 
m [g] × D [Gy]
U [%] × T [d]
In order to achieve euthyroid it is recommended that the de-
sired absorbed dose is 40–80 Gy, whereas for ablation of thyroid 
tissue 200–300 Gy. Activities used in practice range from 3 to 
30 mCi (111–1110 MBq). The method does not require a fixed 
dose of the above calculations and establishes the administration 
of doses depending on the size of the thyroid, and the severity 
of symptoms of hyperthyroidism. The advantage of this method 
is a smaller percentage of patients with early hypothyroidism and 
lower total absorbed dose. A survey conducted among profes-
sionals in Britain showed that 70% of respondents recommended 
a fixed dose. High doses (≥ 0.78 GBq) with I131 are associated with 
higher rates of treatment success and cure than with low-dose 
of I131 (≤ 0.56 GBq). The method of applying fixed dose showed 
higher relapse rates of hyperthyroidism as well as the prevalence 
of hypothyroidism of the following treatment [8, 51–54].
I131 treatment effect in patients with Graves’ disease is not 
immediate, temporary restoration of anti-thyroid treatment after 
administration I131 is indicated in the elderly or in patients with 
severe comorbidities especially with circulatory system diseases. 
A quick check of hyperthyroidism allows you to specify both lithium 
carbonate and I131 [8].
I131 treatment of patients with Graves’ disease is associated 
with risk of developing or worsening of thyroid orbitopathy. On 
this complication, patients are exposed to smoking and high 
levels of antibodies of TRAb. In order to prevent symptoms, it 
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is recommended to cover the steroid prednisone in the form of 
doses of 0.4–0.5 mg/kg of body weight per day, ranging from 1–3 
days before treatment with I131. These doses are maintained for 2–4 
weeks and then reduced over the next month to settle. In cases of 
mild orbitopathy it is possible to use lower doses of the casing 
(approximately 0.2 mg/kg of body weight per day for 6 weeks). Hy-
pothyroidism is a major and frequent undesirable effect. It occurs at 
different frequencies depending on the population and the selec-
tion of the dose. Hypothyroidism can occur at various times after 
I131 treatment from a few weeks to several years. Therefore, these 
patients require periodic checks of TSH levels throughout life. In 
case of TSH increase it is recommended to administer L-thyroxine 
in substitute doses. In some patients with severe Graves’ disease 
and accompanied by hypothyroidism, thyroid orbitopathy after 
treatment with high “ablative” doses of I131 is the expected effect of 
therapy. Of course, as in every case it requires using substitution 
of L-thyroxine [51, 52, 59–64].
I131 treatment can cause a temporary increase in FT4 and 
FT3 in a few days at the therapeutic dose. For initially high con-
centrations of these hormones is the possibility of worsening 
of symptoms, including heart failure, the appearance of atrial 
fibrillation, and even relapse of the thyroid. These patients prior 
to administration of a therapeutic dose of I131 require the prepara-
tion using beta-blockers and anti-thyroid drugs. In the case of 
contraindications to the use of anti-thyroid drugs (for example, 
agranulocytosis, damage to the liver Official Journal of the Mini-
stry of Health — 52 — Pos. 82 52) you can administer I131 under 
the cover of b-adrenolytics drugs and steroids provided that you 
conduct close monitoring of systematic clinical evaluation hormone 
levels (preferably in a hospital). Patients with a large goiter that 
causes narrowing of the trachea should be treated with fractionated 
doses of I131 to prevent transient swelling of thyroid tissue, which 
can lead to respiratory failure and the need for tracheostomy. Rarely 
after administration of higher doses of therapeutic radiation we 
can observe symptoms of thyroiditis that require a non-steroidal 
anti-inflammatory drugs. Due to the very low mass of the iodine 
contained in a dose of I131 drug (about 1/1,000 of the daily supply 
of iodine) this treatment does not cause hypersensitive response 
even in patients with allergy to iodine. The increase of risk of can-
cer, including cancer of the thyroid gland in patients treated with 
I131 has not been clearly shown [51, 52, 64].
Conclusion
To sum up, the key role in monitoring and diagnosis of Graves’ 
disease plays the level of hormones of free thyroxine and tri-
iodothyronine. Helpful is an ultrasound of the thyroid scintigraphy 
which, due to its functional character, is a valuable complement 
morphological study and plays an important role in the diagno-
sis and therapy in patients with Graves’ disease. Due to its low 
cost and much greater sensitivity to measure the concentrations of 
antibodies against the TSH receptor, this test should be performed 
in every patient suspected of having Graves’ disease, especially 
in the absence of beyond thyroid symptoms including Graves’ 
ophthalmopathy.
There is no perfect treatment for Graves’ disease. The rea-
son for this is the absence of therapy directed against primary 
pathogenic mechanisms. Currently available treatments need to 
be thoroughly discussed during the first visit with a specialist, 
because the patient’s awareness about the selection of a treat-
ment constitutes a vital role in the success of therapy. Anti-thyroid 
drugs represent conservative treatment option in which the thy-
roid tissue is not removed [8, 55–57]. Their use is generally safe; 
however, they may be adopted for a period of two years. The main 
disadvantage of using anti-thyroid drugs is too large proportion of 
relapse of hyperthyroidism. Large doses of anti-thyroid drugs al-
low getting euthyreosis faster, but they do not increase the chance 
of securing a lasting remission, but their use increases the risk of 
side effects [10].
Treatment with therapeutic doses of I131 has many advantages. 
The therapy is convenient because it is based on the oral admin-
istration of radioactive sodium iodide in capsule form. The dose 
is absorbed within one hour due to the rapid absorption of sodium 
iodide to the blood in the upper small intestine.
The previous observation suggests that radioactive iodine 
treatment is safe and free of complications which are connected 
with surgical treatment, for example: vocal cord paralysis, hypo-
thyroidism or the occurrence of tetany [58].
Treatment with therapeutic doses of I131 can be performed 
on an outpatient basis what makes this method inexpensive and 
does not require long rehabilitation period comparing to surgery 
and a long-time administration of pharmacological drugs. The exact 
calculation of therapeutic activity of I131, taking into account the ab-
sorbed dose and carried out in a timely checkups, reduces the num-
ber of patients with hypothyroidism and hyperthyroidism relapse.
All these advantages make the I131 treatment of Graves’ disease 
being used more often.
Thyroidectomy should be considered in patients with a large 
goiter and in patients not responding to treatment with anti-thyroid 
drugs or patients who do not give their consent to the administration 
of a therapeutic dose of I131. Thyroidectomy should also be per-
formed in women in the second trimester of pregnancy, after failure 
of treatment with anti-thyroid drugs as well as when there is a fear 
of progress and ophthalmic resulting from radioiodine therapy.
Criteria for the review
The search for original work was conducted in MEDLINE from 
1997 to 2015 that are focused on Graves’ disease. The search 
conditions included: “Graves”, “hyperthyroidism”, “anti-thyroid 
drugs”, “methimazole”, “carbimazole”, “propylthiouracil”, “radioio-
dine therapy” and “thyroidectomy”. Other relevant sources were 
also used, such as the American Thyroid Association guidelines, 
the American Association of Clinical Endocrinologists and chap-
ters from books shown in the bibliography.
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